AZD7798 clinical trials
Also written AZD7798.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2022
How each study uses AZD7798 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AZD7798
- 5
Studies by the year they started
5 studies that test it; most in 2024 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses AZD7798 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Phase IIa Study Evaluating AZD7798 in Crohn's DiseaseActive, not recruitingPhase 2AstraZenecaNCT06450197Written as AZD7798
- Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an IleostomyActive, not recruitingPhase 2AstraZenecaNCT06681324Written as AZD7798
- Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.CompletedPhase 1AstraZenecaNCT06432764Written as AZD7798
- AZD7798 Safety, Tolerability, and Pharmacokinetics After a Single Ascending and Repeat Dose Administrations to Healthy Subjects, and Patients With Crohn's DiseaseCompletedPhase 1AstraZenecaNCT05452304Written as AZD7798
- Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's DiseaseCompletedPhase 1AstraZenecaNCT06053424Written as AZD7798